{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:46:28Z","timestamp":1791773188223,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.amjmed.2021.05.013","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T23:57:07Z","timestamp":1624924627000},"page":"1278-1285.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-6520","authenticated-orcid":false,"given":"Marco","family":"Senzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-5830","authenticated-orcid":false,"given":"Salvatore","family":"Piano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8700-6282","authenticated-orcid":false,"given":"Sarah","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-7178","authenticated-orcid":false,"given":"Alberto","family":"Zanetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sacerdoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-383X","authenticated-orcid":false,"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Bombonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-191X","authenticated-orcid":false,"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0001","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.amjmed.2021.05.013_bib0002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.amjmed.2021.05.013_bib0003","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.amjmed.2021.05.013_bib0004","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.amjmed.2021.05.013_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2016.12.019","article-title":"Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma","volume":"49","author":"Zanetto","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1016\/j.amjmed.2021.05.013_bib0006","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/00007890-200005150-00023","article-title":"Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome","volume":"69","author":"Yerdel","year":"2000","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.amjmed.2021.05.013_bib0007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/hep.1840160515","article-title":"The incidence of portal vein thrombosis at liver transplantation","volume":"16","author":"Nonami","year":"1992","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"Luca","year":"2012","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2013.08.138","article-title":"Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation","volume":"46","author":"Dell'Era","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2021.05.013_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.dld.2009.08.003","article-title":"Portal vein thrombosis, revisited","volume":"42","author":"Primignani","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.amjmed.2021.05.013_bib0011","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"Long-term outcome of splanchnic vein thrombosis in cirrhosis","volume":"9","author":"Senzolo","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0012","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.amjmed.2021.05.013_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinre.2015.02.012","article-title":"Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: a systematic review of the literature","volume":"39","author":"Qi","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL Clinical Practice Guidelines: vascular diseases of the liver","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.amjmed.2021.05.013_bib0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.amjmed.2021.05.013_bib0016","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"La Mura","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.0.CO;2-1","article-title":"Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population","volume":"59","author":"Brigden","year":"1998","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.amjmed.2021.05.013_bib0018","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.amjmed.2021.05.013_bib0019","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","article-title":"Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors","volume":"20","author":"Bauer","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"issue":"21","key":"10.1016\/j.amjmed.2021.05.013_bib0021","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","article-title":"Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia","volume":"70","author":"Schindewolf","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.amjmed.2021.05.013_bib0023","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.amjmed.2021.05.013_bib0024","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.amjmed.2021.05.013_bib0025","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.amjmed.2021.05.013_bib0026","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.amjmed.2021.05.013_bib0027","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.amjmed.2021.05.013_bib0028","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"Cui","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0029","doi-asserted-by":"crossref","first-page":"e88390","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS One"},{"issue":"42","key":"10.1016\/j.amjmed.2021.05.013_bib0030","doi-asserted-by":"crossref","first-page":"e8256","DOI":"10.1097\/MD.0000000000008256","article-title":"Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.amjmed.2021.05.013_bib0031","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/tri.13353","article-title":"Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis","volume":"31","author":"Zanetto","year":"2018","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.amjmed.2021.05.013_bib0032","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.amjmed.2021.05.013_bib0033","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/hep.31443","article-title":"Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features","volume":"72","author":"Zanetto","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.amjmed.2021.05.013_bib0034","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/0091270011409231","article-title":"Renal profiles of anticoagulants","volume":"52","author":"Harder","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0037","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1538-7836.2009.03705.x","article-title":"Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial","volume":"8","author":"Anderson","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2021.05.013_bib0038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.thromres.2020.09.024","article-title":"The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin","volume":"196","author":"Prandoni","year":"2020","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.amjmed.2021.05.013_bib0039","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.thromres.2014.11.032","article-title":"Fondaparinux in the initial and long-term treatment of venous thromboembolism","volume":"135","author":"Pesavento","year":"2015","journal-title":"Thromb Res"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321003892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321003892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:24:15Z","timestamp":1757582655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934321003892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0002934321003892"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.05.013","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}